Preparation and Evaluation of Phospholipid-Based Complex of Standardized Centella Extract (SCE) for the Enhanced Delivery of Phytoconstituents by Saoji, Suprit et al.
St. John Fisher College 
Fisher Digital Publications 
Pharmacy Faculty/Staff Publications Wegmans School of Pharmacy 
11-12-2015 
Preparation and Evaluation of Phospholipid-Based Complex of 
Standardized Centella Extract (SCE) for the Enhanced Delivery of 
Phytoconstituents 
Suprit Saoji 
R.T.M. Nagpur University 
Nishikant Raut 
R.T.M. Nagpur University 
Pradip Dhore 
R.T.M. Nagpur University 
Chandrashekhar D. Borkar 
R.T.M. Nagpur University 
Michael Popielarczyk 
St. John Fisher College, mpp03870@students.sjfc.edu 
See next page for additional authors 
Follow this and additional works at: https://fisherpub.sjfc.edu/pharmacy_facpub 
 Part of the Pharmacy and Pharmaceutical Sciences Commons 
How has open cce s to Fisher Digital Publications 
benefited you? 
Publication Information 
Saoji, Suprit; Raut, Nishikant; Dhore, Pradip; Borkar, Chandrashekhar D.; Popielarczyk, Michael; and Dave, 
Vivek S. (2015). "Preparation and Evaluation of Phospholipid-Based Complex of Standardized Centella 
Extract (SCE) for the Enhanced Delivery of Phytoconstituents." The AAPS Journal 18.1, 102-114. 
Please note that the Publication Information provides general citation information and may not be 
appropriate for your discipline. To receive help in creating a citation based on your discipline, please visit 
http://libguides.sjfc.edu/citations. 
This document is posted at https://fisherpub.sjfc.edu/pharmacy_facpub/364 and is brought to you for free and 
open access by Fisher Digital Publications at St. John Fisher College. For more information, please contact 
fisherpub@sjfc.edu. 
Preparation and Evaluation of Phospholipid-Based Complex of Standardized 
Centella Extract (SCE) for the Enhanced Delivery of Phytoconstituents 
Abstract 
In the present study, a phospholipid-based complex of standardized Centella extract (SCE) was developed 
with a goal of improving the bioavailability of its phytoconstituents. The SCE-phospholipid complex was 
prepared by solvent evaporation method and characterized for its physicochemical and functional 
properties. Fourier transform infrared spectroscopy (FTIR), differential scanning calorimetry (DSC), 
scanning electron microscopy (SEM), photomicroscopy, and powder x-ray diffraction (PXRD) were used to 
confirm the formation of Centella naturosome (CN). The prepared complex was functionally evaluated by 
apparent solubility, in vitro drug release, ex vivo permeation, and in vivo efficacy studies. The prepared CN 
exhibited a significantly higher (12-fold) aqueous solubility (98.0 ± 1.4 μg/mL), compared to the pure SCE 
(8.12 ± 0.44 μg/mL), or the physical mixture of SCE and the phospholipid (13.6 ± 0.4 μg/mL). The in vitro 
dissolution studies revealed a significantly higher efficiency of CN in releasing the SCE (99.2 ± 4.7, % w/w) 
in comparison to the pure SCE (39.2 ± 2.3, % w/w), or the physical mixture (42.8 ± 2.09, % w/w). The ex 
vivo permeation studies with the everted intestine method showed that the prepared CN significantly 
improved the permeation of SCE (82.8 ± 3.7, % w/w), compared to the pure SCE (26.8 ± 2.4, % w/w), or the 
physical mixture (33.0 ± 2.7, % w/w). The in vivo efficacy studies using the Morris Water Maze test 
indicated a significant improvement of the spatial learning and memory in aged mice treated with CN. 
Thus, drug-phospholipid complexation appears to be a promising strategy to improve the aqueous 
solubility and bioavailability of bioactive phytoconstituents. 
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Preparation and evaluation of phospholipid-based naturosomes of Standardized Centella 
Extract (SCE) for the enhanced delivery of phytoconstituents 
Abstract 
In the present study, a phospholipid-based complex of Standardized Centella Extract (SCE) was 
developed with a goal of improving the bioavailability of its phytoconstituents. The SCE-
phospholipid complex was prepared by solvent evaporation method, and characterized for its 
physicochemical and functional properties. Fourier transform infrared spectroscopy (FTIR), 
differential scanning calorimetry (DSC), scanning electron microscopy (SEM), 
photomicroscopy, and powder x-ray diffraction (PXRD) were used to confirm the formation of 
CN (Centella Naturosome). The prepared complex was functionally evaluated by apparent 
solubility, in-vitro drug release, ex-vivo permeation, and in-vivo efficacy studies.  The prepared 
CN exhibited a significantly higher (12-fold) aqueous solubility (98.01 ± 1.37 μg/mL), compared 
to the pure SCE (8.12 ± 0.44 μg/mL), or the physical mixture of SCE and the phospholipid 
(13.58 ± 0.35 μg/mL). The in-vitro dissolution studies revealed a significantly higher efficiency 
of CN in releasing the SCE (99.23 ± 4.71, % w/w) in comparison to the pure SCE (39.21 ± 2.31, 
% w/w), or the physical mixture (42.8 ± 2.09, % w/w). The ex-vivo permeation studies with the 
everted intestine method showed that the prepared CN significantly improved the permeation of 
SCE (82.83 ± 3.73, % w/w), compared to the pure SCE (26.84 ±2.41, % w/w), or the physical 
mixture (32.99 ±2.7, % w/w). The in-vivo efficacy studies using Morris Water Maze test 
indicated a significant improvement of the spatial learning and memory in aged mice treated with 
CN. Thus, drug-phospholipid complexation appears to be a promising strategy to improve the 
aqueous solubility and bioavailability of bioactive phytoconstituents. 
Introduction 1 
The use of natural products in the management of several diseases/disorders have gained 2 
popularity in recent years. However, their use as pharmaceutical drug products is limited due to 3 
the poor oral bioavailability of bioactive phytoconstituents. The poor bioavailability of these 4 
pharmacologically active components is mainly attributed to the high molecular weight/size, 5 
poor aqueous/lipid solubility, and lower plasma membrane permeability, thereby limiting their 6 
use for the effective treatment of various diseases and disorders (1, 2).  7 
Improving the bioavailability of these bioactive compounds via improving the solubility 8 
and the permeability remains a major bottleneck in the development of pharmaceutical drug 9 
products from these entities. Among the several approaches explored in recent years for the 10 
improvement of bioavailability of drugs, drug-phospholipid complexes appear to be among the 11 
promising ones. Incorporating bioactive phytoconstituents into phospholipid molecules is 12 
reported to improve the aqueous solubility, the membrane permeability, and hence the systemic 13 
absorption and bioavailability of the active phytoconstituents. Such complexes are appropriately 14 
called Phytosomes, Herbosomes, or Naturosomes (3, 4). Studies have reported success in 15 
improving the pharmacological profiles of several bioactive phytoconstituents using drug-16 
phospholipid complexation technique (5-9).  17 
Alzheimer’s disease (AD) is an irreversible, neurodegenerative disorder resulting in a 18 
progressive decline of cognitive and functional abilities, with impairment of memory and 19 
thinking skills (10). Alzheimer’s Association projects the incidence of AD to 1 million people 20 
annually, and estimates the total prevalence of the disorder to 11-16 million people, by the year 21 
2050 (11). Current AD interventions include symptomatic treatment with cholinesterase 22 
inhibitors (ChEIs) such as donepezil, and N-methyl-D-aspartase receptor antagonists such as 23 
memantine (12). However, the progression of the disease, and the associated neuronal 24 
degeneration continues, in addition to the  adverse effects of this treatment (13). In 2004, the 25 
USFDA approved Galantamine, a phytoconstituent obtained from Galanthus nivalis, for the 26 
treatment of AD with the reported mechanism being the inhibition of acetyl cholinesterase (14). 27 
Recently, some herbal extracts such as those of Ginkgo biloba, and other phytochemicals such as 28 
evodamine have also been explored for their anti-AD properties in animals and humans (15-19).  29 
Centella asiatica Linn. (Apiaceae), a perennial creeper found throughout most tropical 30 
and subtropical countries, is reported to be useful for anxiety, memory enhancement, and 31 
neuroprotection (20). The major chemical constituents reported to be responsible for its 32 
pharmacological activity are triterpenes based on steroidal moieties, such as asiaticoside, asiatic 33 
acid, madecassoside, and madecassic acid (21). Several pharmaceutical products containing C. 34 
asiatica are commercially available, and are recommended for enhancing memory in patients 35 
with memory deficit (22). The usefulness of any pharmaceutical product depends on the safety, 36 
efficacy, and the quality of that product. A Quality by Design (QbD) approach is now considered 37 
to be an ideal pathway to ensure the development of a quality product, and the minimization of 38 
product variabilities. QbD is broadly defined as a scientific, risk-based, holistic, and a proactive 39 
approach to pharmaceutical development that begins with predefined objectives, and emphasizes 40 
the understanding and control of the product and processes based on sound science, and quality 41 
risk management (23). Despite the commercial availability of several pharmaceutical products 42 
containing extracts of Centella asiatica, the issue of the low aqueous solubility of the extract 43 
remains practically unaddressed. 44 
 Thus, the primary goal of the current study was to evaluate the feasibility of enhancing 45 
the aqueous solubility of Standardized Centella Extract (SCE) by preparing its vesicular complex 46 
with hydrogenated soy phosphatidylcholine (Phospholipon® 90H). This complex is hereby 47 
referred to as Centella Naturosome (CN). To address this objective, CN were prepared using a 48 
solvent evaporation method. The formulation and the process variables for the preparation of the 49 
CN were optimized using a QbD approach. Response surface analysis by the means of central 50 
composite design was employed for the optimization of the critical process parameters (CPP) on 51 
the SCE entrapment rate of CN. The prepared CN were evaluated for their physicochemical, 52 
functional, and preliminary pharmacological properties.  53 
Materials and methods 54 
Materials 55 
The Standardized Centella Extract (SCE), containing ~30% triterpenes was obtained from 56 
Natural Remedies Ltd, Bangalore, India. The identity of the SCE was confirmed by HPLC 57 
analysis. Hydrogenated soy phosphatidylcholine (Phospholipon® 90H) was generously gifted by 58 
Lipoid, Ludwigshafen, Germany. All other chemicals and reagents used were of analytical grade. 59 
Analysis of the triterpenes present in SCE 60 
The concentrations of the triterpenes present in SCE i.e. asiaticoside, asiatic acid, madecassoside, 61 
and madecassic acid, were determined using a modified, reverse-phase high performance – liquid 62 
chromatography (RP-HPLC) method previously described by Hashim et al. (21). Briefly, the 63 
HPLC system (Model: Prominence, Shimadzu Corporation, Kyoto, Japan) with LC solution 64 
software, equipped with a LC-20AD HPLC pump, a manual rheodyne sample injector, and a 65 
SPD-M20A detector were used. The mobile phase was composed of acetonitrile and water 66 
(25:75, v/v), at a flow rate of 1.5 mL/min. A Micra- NPS RP18 column (33×8.0×4.6 mm, 1.5 67 
μm) was used as a stationary phase, and the detector wavelength was 210 nm at room 68 
temperature. Throughout the study, the suitability of the chromatographic system was monitored 69 
by calculating the trailing/asymmetry factor, theoretical plates and the relative standard deviation 70 
(RSD). The calibration curves for individual triterpenes were constructed by analyzing eight 71 
concentrations of the standard solution for each triterpene, and plotting peak areas versus 72 
concentration. The method was validated by analyzing the different validation characteristics 73 
such as linearity, accuracy and precision. 74 
Preparation of Centella Naturosome (CN) 75 
The CN were prepared by slightly modifying the solvent evaporation method described by 76 
Bhattacharyya et al. (24). Briefly, different ratios, i.e. 0.5:1, 1.01:1, 1.75:1, 2.49:1 or 3:1, of 77 
Phospholipon® 90H and SCE were placed in a 100 mL round bottom flask, and 40 mL of ethanol 78 
was added to the mixture. The reaction was controlled and maintained at various temperatures, 79 
i.e. 40°C, 44°C, 50°C, 56°C, or 60°C using a water bath. The reaction was carried out for 80 
different durations, i.e. 1h, 1.4h, 2h, 2.6h or 3 h. The resulting clear solution was evaporated to 81 
2–3 mL, and an excess of n-hexane was added to it with continuous stirring. The dispersion 82 
formed was then precipitated, filtered, and dried under vacuum to remove any traces of solvents. 83 
The resulting CN were stored at room temperature, in amber colored glass vials, flushed with 84 
nitrogen, for further testing. 85 
Quality by Design (QbD) based design of experiments 86 
A QbD-based approach using a central composite design to obtain a response surface design was 87 
employed to systematically study the combined influence of the formulation and process 88 
variables such as the phospholipid-to-drug ratio (X1, w:w), the reaction temperature (X2, ◦C), and 89 
the reaction time (X3, h) on the Critical Quality Attributes (CQAs) of the product i.e. the 90 
entrapment efficiency. Using this design, the influence of three factors was evaluated, and the 91 
experimental trials were carried out at all 20 possible combinations (25, 26). A statistical model 92 
incorporating interactive and polynomial terms was used to evaluate the response employing the 93 
following equation (1): 94 
 95 
 96 
Where,  was the dependent variable,  is the arithmetic mean response of the 20 runs, and  is 97 
the estimated coefficient for the factor . The main effects (  and ) represented the average 98 
result of changing one factor at a time from its low to high value. The interaction terms ( , 99 
, ) showed how the response changes when all three factors were simultaneously 100 
changed. The polynomial terms ( , , and  ) were included to investigate on-linearity. The 101 
level values of the three factors, the real values of the central composite design batches, and the 102 
resulting entrapment efficiencies are shown in table 1 and 2. 103 
Entrapment efficiency of CN 104 
The entrapment efficiency, i.e. the SCE (total triterpenes content) entrapped in the naturosome 105 
was determined using a combination of methods described in the literature (27, 28). Briefly, 106 
accurately weighed (100 mg) CN powder was dispersed in 10 mL chloroform. The CN and 107 
Phospholipon® 90H both were easily dissolved in the chloroform. The SCE not entrapped in the 108 
CN was collected as a sediment and assayed by HPLC. The entrapment efficiency of the 109 
prepared CN was calculated using the following equation (2):  110 
 111 
Where,  = Total concentration of SCE, and   = SCE contained in the filtrate. 112 
Determination of SCE content in CN 113 
The SCE content in the CN was determined by HPLC method described above. The drug content 114 
was calculated using equation (3) below, previously described by Bhattacharya et al.(29). 115 
 116 
Physico-chemical characterization of CN 117 
Photomicroscopy 118 
For the microscopic characterization of the prepared naturosomes, a suspension containing 119 
approximately 100 mg of the naturosome powder was transferred to a glass tube and diluted with 120 
10 mL Phosphate Buffer Saline (PBS, pH 7.4). The suspended vesicles were then mounted on a 121 
clear glass slide and photomicrographs were captured with a microscope (Model: DM 2500, 122 
Leica Microsystems, Germany) under 20x magnification. 123 
Scanning Electron Microscopy (SEM) 124 
The CN powder obtained from the optimized formulation batches was sprinkled on a double-125 
sided carbon tape, and the tape was placed on a brass stub. The surface powder was coated with a 126 
thin layer of palladium using the auto fine coater (Model: JFC1600, Jeol Ltd., Tokya, Japan). 127 
The palladium coated samples were observed using a Scanning Electron Microscope (Model: 128 
JSM-6390LV, Jeol Ltd, Tokyo, Japan) equipped with a digital camera, at 10 KV accelerating 129 
voltage.   130 
Particle size and zeta potential analysis 131 
The particle size analysis of the prepared CN was carried out using Photon Correlation 132 
Spectroscopy (PCS), with dynamic light scattering on a Zetasizer® nano (Model: Zen 3600, 133 
Malvern Instruments, Malvern, UK) equipped with a 5mW He-Ne laser with a wavelength 134 
output of 633 nm. The measurements were carried out at 25 °C, at an angle of 90° and a run time 135 
of at least 40-80 sec. Water was used as a dispersant. The zeta potential was measured by 136 
Smoluchowski’s equation from the electrophoretic mobility of naturosomes (30). All 137 
measurements were performed in triplicate.  138 
Fourier Transform Infrared (FTIR) Spectroscopy 139 
The infrared spectra of neat SCE, Phospholipon® 90H, the physical mixture of SCE with 140 
Phospholipon® 90H (PM), and the prepared CN were obtained from an FTIR spectrophotometer 141 
(Model: IR Prestige-21, Shimadzu, Japan) equipped with an Attenuated Total Reflectance (ATR) 142 
accessory. The analysis of the samples was carried out using diffuse reflectance spectroscopy 143 
using KBr compacts. The influence of the residual moisture was theoretically removed by 144 
subjecting the samples to vacuum drying before obtaining any spectra. Each sample analysis 145 
included 45 scans, at a resolution of 4 cm−1 in the wavelength range 4000 to 600 cm−1. 146 
Differential scanning calorimetry (DSC) 147 
The thermal analysis of the samples (SCE, Phospholipon® 90H, PM, and CN) was carried out 148 
using a differential scanning calorimeter (Model: Q20, TA Instruments, Inc., New Castle, DE, 149 
USA). The analysis was performed under a purge of dry nitrogen gas (50 ml/min). High-purity 150 
indium was used to calibrate the heat flow and the heat capacity of the instrument. The samples 151 
(~5 mg) were held in open standard aluminum pans. Each sample was subjected to a single 152 
heating cycle from 0°C to 400°C at a heating rate of 10°C/min. The peak transition onset 153 
temperatures of samples were analyzed using the Universal Analysis software version 4.5A, 154 
build 4.5.0.5 (TA Instruments, Inc., New Castle, DE, USA) (31). 155 
Powder x-ray diffraction (PXRD) 156 
The polymorphic state of the samples (SCE, Phospholipon® 90H, PM, and CN) was evaluated 157 
using a powder x-ray diffractometer (Model: D2 Phaser, Bruker AXS, Inc., Madison, WI, USA), 158 
equipped with a Bragg-Brentano geometry (θ/2θ) optical setup. The samples were scanned with 159 
the diffraction angle increasing from 2º to 90º, 2θ angle, with a step-angle of 0.2º 2θ and a count 160 
time of 0.5 seconds. 161 
Functional evaluation of CN 162 
Apparent solubility analysis 163 
The apparent solubility of the samples was determined by a method previously described by 164 
Singh et al. (32). Briefly, an excess of SCE and CN were added to 10 mL of water or n-Octanol 165 
in sealed glass containers at room temperature (25°C). The liquid was agitated for 24 h, followed 166 
by centrifugation for 30 min at 4,000 RPM. The supernatant was filtered through a membrane 167 
filter (0.45 μ). 1 mL of this filtrate was mixed with mobile phase to prepare appropriate dilutions, 168 
and the samples were analyzed at 210 nm using the RP-HPLC method described above. 169 
In-vitro drug release (dissolution) 170 
The in-vitro dissolution study was carried out using the method described previously by Zhang et 171 
al (33). Accurately weighed samples equivalent to 50 mg of SCE were added to the surface of 172 
the stirred dissolution medium (900 mL phosphate buffer, pH 6.8) at the beginning of the study 173 
in a USP type II dissolution apparatus (Model: TDT-06T, Electrolab India Pvt. Ltd., India). The 174 
dissolution was carried out at 100 rpm and 37ºC. Samples (10 mL) from the dissolution medium 175 
were withdrawn at regular time intervals, and replaced with an equal volume of fresh medium to 176 
maintain sink conditions. The samples were filtered through a membrane filter (0.45μ), diluted 177 
suitably with mobile phase to prepare dilutions, and analyzed using the RP-HPLC method 178 
described above. 179 
Dissolution efficiency (DE) 180 
The dissolution efficiency (DE) of the SCE, PM, and CN in the phosphate buffer saline was 181 
evaluated at 12 h. The dissolution efficiency was calculated using the equation (4) below, 182 
previously described by Anderson et al. (34). 183 
 184 
Where,  is the percentage of dissolved drug.  is the area under the dissolution curve between 185 
time points  and  expressed as a percentage of the curve at maximum dissolution, , over 186 
the same time period. The integral of the numerator, i.e. the area under the curve was calculated 187 
by a model independent trapezoidal method as defined by the equation (5) below. 188 
 189 
Where  is the ith time point,  is the percentage of dissolved drug at time . 190 
Ex-vivo permeability  191 
Perfusion apparatus: The apparatus used in this study was previously described by Dixit et al. 192 
(35)  which consisted of a two glass tubes held together by a glass joint on the upper end with 193 
open tapering ends facing towards each other. A provision for mounting the tissue is facilitated 194 
in the form of a bulge at the ends of both tubes. The dimensions of the apparatus (18cm × 4cm × 195 
2cm) are such that it can be conveniently set up in a 250 mL glass measuring cylinder. After 196 
mounting the everted intestinal segment on the apparatus the whole assembly is kept in a glass 197 
measuring cylinder; the inside of the glass tubes serve as the receiver compartment and the 198 
outside serves as the donor compartment.  199 
Isolation and eversion of the intestine: Ethical clearance for the handling of experimental 200 
animals was obtained from the institutional animal ethics committee (IAEC) formed for this 201 
purpose. The Sprague-Dawley® rats (200-250 g) were fasted overnight. The rat was euthanized 202 
humanely by cervical dislocation, midline incision was given to open the abdomen and the 203 
intestine was carefully maneuvered to identify the ileo-cecal junction. About 7cm long intestine 204 
(jejunum) was removed from the mesenteric attachments carefully without damaging the 205 
intestine. The isolated piece of intestine was thoroughly washed with Kreb’s solution, everted 206 
using glass rod, and transferred to a petri dish containing Kreb's solution. A 6cm everted segment 207 
was used for permeability experiments. 208 
Permeability determination: The everted piece of intestine was mounted between the two tapered 209 
ends of the perfusion apparatus. The perfusion apparatus was filled with Kreb’s solution and 210 
immersed in the measuring cylinder (250 mL) containing SCE, PM, or CN (100 μg/mL) in 250 211 
mL Kreb’s solution. The whole assembly was placed on a constant temperature (37 °C) magnetic 212 
stirrer and the content stirred at 25 RPM. Additionally, the Kreb’s solution was constantly 213 
aerated with carbogen (Oxygen: Carbon dioxide (95:5) mixture). The samples were collected at 214 
15 min interval up to three hours and analyzed by HPLC for estimation of permeability. 215 
Preliminary pharmacological evaluation (in-vivo efficacy) 216 
Animals: Young (3-4 months), and aged (22-24 months), male Swiss albino mice were group 217 
housed under constant room temperature (25 ± 2 °C), relative humidity (50 - 70% RH), and 218 
maintained on a 12 hour: 12 hour light: dark cycle. Food and water were given ad libitum except 219 
during the experiment. All procedures and protocols employed in the study were approved and 220 
carried out under strict compliance with the Institutional Animal Ethics Committee, Department 221 
of Pharmaceutical Sciences, R. T. M. Nagpur University, Nagpur, MS, India. 222 
Morris Water Maze Test (MWM): The MWM test was performed to compare the 223 
pharmacological efficacy of the prepared CN with that of SCE in spatial learning and memory in 224 
mice. MWM test is among the most widely used behavioral models employed for screening of 225 
anti-Alzheimer’s activity in the rodents. The standard protocol previously described by Vorhees 226 
et al. was employed with some modifications (36).  Briefly, the animals were acclimatized to the 227 
laboratory conditions for a week before performing the actual experiments. MWM consists of a 228 
large circular pool measuring 90 cm in diameter and 40 cm in height. The maze was filled with 229 
water (25 °C) to a height of 30 cm, and rendered opaque using milk. The pool was arbitrarily 230 
divided into four compass quadrants, and a white escape platform (10 cm in diameter) was 231 
submerged in one of the quadrants, one cm below the water surface.  The location of platform 232 
remained fixed for all four days of training sessions. 233 
The animals were divided into seven groups with six animals in each group (n=6), i.e. 234 
group 1: young mice (vehicle), group 2: aged mice (vehicle), group 3: Phospholipon® 90H 235 
(900 mg/kg), group 4: piracetam (200 mg/kg), group 5: SCE (300 mg/kg), group 6: PM 236 
(equivalent to 300 mg/kg SCE),and group 7: CN (equivalent to 300 mg/kg SCE). The doses 237 
used in the present study were reported effective in the animals (37, 38). All animals received 238 
their respective treatments orally, each day, one hour before the experiment. Each mouse was 239 
given four training sessions per day, at an interval of 10 minutes between the training sessions, 240 
for four consecutive days.  The starting locations for the animals varied quasi-randomly, and the 241 
cutoff time was fixed at 120 seconds.  The length of time taken by the animal to locate the 242 
platform was measured as escape latency. If the animal failed to escape within 120 seconds, it 243 
was manually placed on the platform for 30 seconds, and the escape latency was recorded as 120 244 
seconds.  A single 120 second probe trial was also conducted on the 5th day (24 hours after the 245 
last acquisition trial), to measure the time spent in the target quadrant, as a measure of memory 246 
retention. 247 
Results and discussion 248 
Preparation of Centella Naturosome (CN) 249 
The initial investigation of the influence of factors revealed that all the studied factors, i.e. the 250 
phospholipid-to-drug ratio, the reaction temperature, and the reaction time had a significant 251 
influence on the entrapment efficiency of the prepared naturosomes. The results of the 252 
entrapment efficiency (%) are shown in Table 2. The measured values from the experimental 253 
trials revealed a wide range (58.1– 95.1, % w/w) entrapment efficiencies (Table 2). The fitted 254 
polynomial equations relating the response (entrapment efficiency, % w/w) to the transformed 255 
factors are shown in Figure 1. The polynomial equations could be used to draw conclusions after 256 
considering the magnitude of the coefficient, and its associated mathematical sign, i.e., positive 257 
or negative. The results from the Figure 1 also indicated that all the coefficients, i.e. , , , 258 
, , , , , and  were statistically significant (p < 0.05). The value of correlation 259 
coefficient (R2) was found to be 0.9369, indicating a good fit to the quadratic model. The 260 
multiple regression analysis (Figure 1) revealed that the coefficients , , and   were 261 
positive. This indicated that the entrapment efficiency increased with increasing , , and . 262 
The data further indicated that the quadratic model is statistically significant (Fcritical value 263 
= 16.5; p <0.001) (Suppl. Table 1). 264 
Based on the central composite design, the response surface and contour plots 265 
depicting the changes in the entrapment efficiency (%) as a function of , , and  were 266 
created (Suppl. Figure 1). The data from all 20 batches of the central composite design were 267 
used for generating interpolated values using Design Expert 9, version 9.0.4.1 (Stat-Ease, Inc., 268 
Minneapolis, MN). The response surface and contour plots indicated a strong influence of the 269 
studied factors , , and  on the entrapment efficiency. Increasing levels of , , and  270 
were found to be favorable conditions for obtaining higher entrapment efficiency. Based on these 271 
observations, along with the multiple regression model, the optimal values of the studied factors, 272 
i.e. the phospholipid-to-drug ratio, the reaction temperature, and the reaction time were 3:1, 60 273 
°C, and 3 hours, respectively. 274 
Validation of the model 275 
In order to validate the developed model, an additional batch of CN was prepared. This 276 
validation batch was prepared using the optimal settings of the formulation and process variables 277 
from the model, i.e.  , , and  values of 3:1, 60 °C, and 3 hours, respectively. The predicted 278 
entrapment efficiency of the CN obtained from model, as well as the actual entrapment 279 
efficiency achieved from the prepared formulation were compared (Suppl. Table 2). The 280 
average entrapment efficiency of SCE in naturosomes prepared under the optimized conditions 281 
was found to be 93.9 ± 1.3 %. These values compared well with the model-predicted value, i.e. 282 
95.0 %, indicating the practicability, and the validity of the developed model. The bias (%), 283 
calculated using the equation (6) below was also found to be less than 3% (1.2%), indicating the 284 
relative robustness of the model (39). 285 
 286 
Physico-chemical characterization of the prepared CN 287 
Photomicroscopy and Scanning electron microscopy (SEM) 288 
The results from the initial morphological characterization of SCE and the prepared CN 289 
showed that the SCE appeared to be irregularly shaped, polydispersive agglomerates made 290 
up of small, crystalline particles (Suppl. Figure 2A). Whereas, the prepared CN appeared 291 
to have a dramatically different morphology (Suppl. Figure 2B). These particles were much 292 
larger entities, with a relatively rough surface; and appeared to consist of multiple layers, with 293 
possibly entrapping the SCE crystals (shown by the red pointer). 294 
 The prepared CN were further analyzed by SEM for their surface morphology 295 
[Suppl. Figure 3 (A, B, and C)]. The electron micrographs at different magnifications i.e. 1000x 296 
(3A), 3000x (3B), and 6000x (3C) revealed the formation of multi-layered vesicles of 297 
hydrogenated soy phosphatidylcholine. The initial morphological characterization indicated the 298 
successful formulation of phospholipid-based vesicular complex (naturosome) of SCE. 299 
Particle size and zeta potential analysis 300 
The mean particle size and the zeta potential values of the prepared CN were carried out 301 
using dynamic light scattering technique [Suppl. Figure 4(A andB)]. The mean particle size 302 
of CN was found to be 450.1 ± 20.0 nm. The surface area/volume (SA/V) ratio of most particles 303 
is inversely proportional to the particle size. Thus, smaller particles of the CN, having a higher 304 
SA/V, makes it easier for the entrapped drug to be released from the naturosome via diffusion 305 
and surface erosion. They also have the added advantage for the drug-entrapped naturosomes to 306 
penetrate into, and permeate through the physiological drug barriers. LeFevre et al. and Savic et 307 
al. have previously suggested that larger particles (≤ 5 mm) are taken up via the lymphatics, 308 
while the smaller particles (≤ 500 nm) can cross the epithelial cell membrane via endocytosis 309 
(40, 41). Zeta potential is another important index commonly used to assess the stability of the 310 
naturosomes. The zeta potential of the prepared CN was found to be -35.0 ± 1.9 mV. These 311 
results are in agreement with previous reports, which mentions that the zeta potential values of 312 
greater than −30 mV are considered acceptable, and are indicative of a good physical stability 313 
(42, 43). 314 
Fourier transform infrared Spectroscopy (FTIR) 315 
The results from the FTIR analyses of the SCE, Phospholipon® 90H, the physical mixture of 316 
SCE with Phospholipon® 90H (PM), and the prepared CN are shown in Figure 2 (A, B, C, and 317 
D, respectively). The FTIR spectrum of SCE (Figure 6A) exhibited a broad peak at 3365 cm-1 318 
representing the aliphatic alcoholic (–OH) group substituted on the cyclic ringed structure. The 319 
C-H stretching signal at 2926 cm-1 relates to the characteristic feature of the triterpene ring 320 
structure. The triterpene also exhibited a C=O stretching around 1710 cm-1, along with a C=C 321 
stretching signal at 1662 cm-1 as an associated peak possibly representing the alkene nature of 322 
neighboring ring attachments. The FTIR spectrum of the SCE further exhibited the aromatic 323 
nature of the basic ring nucleus, with aromatic stretching signals in the region of 1602 cm-1 and 324 
1563 cm-1. Prominent peaks observed at 1164 cm-1 and 1088 cm-1 typically relates to the 325 
presence of acidic functional groups (-COOH) on the molecule.   326 
The FTIR spectrum of Phospholipon® 90H revealed the characteristic C–H stretching 327 
signal present in the long fatty acid chain at 2,918 cm-1 and 2,850 cm-1 respectively. In addition, 328 
a C=O stretching band at 1,738 cm-1 in the fatty acid ester, a P=O stretching band at 1,236 cm-1, 329 
a P–O–C stretching band at 1,091 cm-1, and a -N+(CH2)3 stretching at 970 cm-1 were also 330 
observed in the spectrum. In the FTIR spectrum of the prepared CN, the SCE peaks at 1602 cm-1 331 
and 1662 cm-1 were found to have disappeared, with an emergence of a peak at 1635 cm-1 332 
indicating a possibility of conjugation of the two compounds, leading to the formation of a 333 
naturosome. The disappearance of peak at 1563 cm-1 (exhibiting the aromatic ring stretching) 334 
may be due to the weakening, or removal, or shielding by the phospholipid molecule, which may 335 
further support the formation of naturosome. This phenomenon may be explained as occurring 336 
due to the entrapment/packing of the SCE in the hydrophobic cavity of the formed phospholipid 337 
vesicle, and being held by van der Waals forces, and other hydrophobic interactions (44). The 338 
presence of the peaks at 1468 cm-1, 1418 cm-1, and 1378 cm-1 exhibits the C-H bending and 339 
rocking. These peaks were found in both Phospholipon® 90H, as well as in the physical mixture; 340 
and remained consistent in the complex with a negligible shift from original scale, indicating 341 
their lack of involvement in the formation of the naturosome. 342 
Differential scanning calorimetry (DSC) 343 
The interactions between multiple components of a formulation is commonly analyzed by DSC.  344 
Such interactions are typically observed as the elimination of endothermic peaks, appearance of 345 
new peaks, changes in peak shape and its onset, peak temperature/melting point and relative peak 346 
area, or enthalpy (45). The Figure 3 shows the DSC thermograms of (A) pure SCE, (B) 347 
Phospholipon® 90H, (C) PM, and (D) CN. The pure SCE (Figure 3A) revealed a broad 348 
endothermic peak around 94.4 ºC. Phospholipon® 90H showed two sharp endothermic peaks at 349 
125.2 ºC and 182.5 ºC, respectively (Figure 3B). The first peak (at 125.2 ºC) is likely due to the 350 
melting of phospholipid. The second peak (at 182.5 ºC) appears to be due to the phase-transition 351 
from gel to a liquid-crystalline state, and the carbon-chain in the phospholipid may have perhaps 352 
undergone other isomeric or crystal changes (46). In the physical mixture (PM) of the SCE and 353 
Phospholipon® 90H (Figure 3C), the two peaks are observed at 100.9 ºC and at 123.6 ºC. It may 354 
be assumed that with the rise in temperature, the Phospholipon® 90H melts, and the SCE gets 355 
dissolved in it, partly forming the naturosome. The thermogram of the CN exhibits two partially 356 
fused, broad endothermic peaks at 68.8 ºC and 85.9 ºC, respectively (Figure 3D). These peaks 357 
differed from the peak of SCE and Phospholipon® 90H. A reduction in the melting point and 358 
enthalpy may account for the increased solubility, and reduced crystallinity of the drugs (47). It 359 
was thus evident that the original peaks of SCE and Phospholipon® 90H disappeared from the 360 
thermogram of the CN, and the phase transition temperature was lower than that of 361 
Phospholipon® 90H, thus confirming the formation of the drug-phospholipid complex. These 362 
findings are in agreement with those reported in the literature, and the interaction between the 363 
SCE and Phospholipon® 90H can be attributed to a combination of forces such as hydrogen 364 
bonding and van der Waals interactions, and can be considered as an indication of drug 365 
amorphization and/or complex formation, as supported by IR spectroscopy (48, 49). The 366 
interaction of the SCE with the polar region of Phospholipon® 90H may have been followed by 367 
the entrapment of SCE with the long chain hydrocarbon tail of phospholipid molecules. This 368 
resulted in the sequential decrease in phospholipid hydrocarbon chains, and the disappearance of 369 
the second endothermic peak of Phospholipon® 90H with a reduction in the phase transition 370 
temperature (45). 371 
Powder x-ray diffraction (PXRD) 372 
The Figure 4 displays the powder x-ray diffraction patterns of (A) SCE, (B) Phospholipon® 90H, 373 
(C) PM, and (D) CN. The diffractogram of the SCE (Figure 4A) revealed sharp crystalline peaks 374 
at 2θ = 46.0º, 41.0º, 32.0º, and 28.0º.  A single diffraction peak was observed at 2θ = 21.0º for 375 
Phospholipon® 90H (Figure 4B). The physical mixture (PM) showed most of the peaks 376 
associated with the SCE and Phospholipon® 90H (Figure 4C). In comparison to the physical 377 
mixture, the diffractogram of the CN revealed the disappearance of most of the crystalline peaks 378 
associated with the SCE (Figure 4D). These results were in agreement with the previously 379 
reported studies, where the disappearance of the Active Pharmaceutical Ingredient (API) peaks 380 
was associated with the formation of API-Phospholipid complexes (44, 48).  The disappearance 381 
of the SCE crystalline peaks thus confirmed the formation of SCE-Phospholipid complex. It may 382 
then also be concluded that the SCE in the Phospholipon® 90H matrix may be present either as a 383 
molecularly dispersed, or an amorphous state (50). 384 
Functional evaluation of CN 385 
Apparent solubility 386 
The results of the measured apparent solubilities of the pure SCE, the physical mixture of SCE 387 
and Phospholipon® 90H (PM), and the prepared SCE- Phospholipon® 90H complex (CN) are 388 
shown in the Table 3. It was observed that the pure SCE had poor aqueous solubility (~8 389 
μg/mL), and a relatively higher solubility in n-Octanol (~325 μg/mL), indicating a rather 390 
lipophilic nature of the drug. The physical mixture (PM) revealed a non-significant change in the 391 
n-Octanol solubility, and a modest increase (~1.5 times) in the aqueous solubility. The prepared 392 
SCE- Phospholipon® 90H complex (CN) however, showed a dramatic, and a significant (over 393 
12-fold) increase in the aqueous solubility. This increase in the solubility of the prepared 394 
complex may be explained by the partial amorphization (reduced molecular crystallinity) of the 395 
drug, and the overall amphiphilic nature of the naturosome (32, 51). 396 
In-vitro drug release (dissolution) 397 
The results of in-vitro drug release studies are shown in the Figure 5. The 12 hours dissolution in 398 
the phosphate buffer (pH-6.8) revealed that, the pure SCE showed the slowest rate of dissolution, 399 
i.e. at the end of the dissolution period only about 39% w/w of SCE was dissolved. The 400 
dissolution rate of the physical mixture was found not to be significantly different (~42% w/w 401 
dissolved in 12 hours) compared to the pure SCE. The prepared CN, however revealed a 402 
significantly faster release of SCE at the end of dissolution period.  The dissolution profile of the 403 
CN followed a near zero-order release, and at the end of 12 hours, over 99% w/w SCE was 404 
observed to be released from the CN. The dissolution rate is largely influenced by the crystal 405 
morphology and the wettability of the solids, and the improved dissolution rate of SCE from the 406 
CN may be explained by the improved solubility, and the partially disrupted crystalline phase 407 
(amorphous form) in the prepared naturosome (5, 50). The relatively higher amorphous state of 408 
the naturosome, and their increased water-solubility may have had a positive impact on the 409 
cumulative release of the drug.  410 
Dissolution efficiency (DE) 411 
The dissolution efficiencies of the pure SCE, the physical mixture of SCE and 412 
Phospholipon® 90H (PM), and the prepared SCE- Phospholipon® 90H complex (CN) 413 
calculated from the in-vitro release studies in phosphate buffer (pH-6.8) were calculated 414 
using the equation 4 above (Suppl. Table 3). The prepared CN showed a significantly 415 
(P<0.001) improved dissolution efficiency compared to the pure SCE. Almost 2.4-fold increase 416 
in the DE was observed for CN in PBS at the end of 12 hours, compared to the pure SCE. This 417 
significant increase can be attributed to the enhancement of SCE solubility in the prepared 418 
naturosome. A marginal, but a statistically significant (p < 0.01) increase in dissolution 419 
efficiency of SCE in physical mixture, compared to the pure SCE was also observed. The 420 
solubilizing ability of the phospholipids, owing to their amphiphilic nature is likely the reason 421 
for this observed increase in the release of SCE. 422 
Ex-vivo permeability 423 
The results of the ex-vivo permeability study as carried out with the everted intestine method on 424 
the pure SCE, the physical mixture of SCE and Phospholipon® 90H (PM), and the prepared 425 
SCE- Phospholipon® 90H complex (CN) are shown in the Figure 6. The permeability of the 426 
tested samples appeared to follow the trends observed in the in-vitro release study. It was 427 
observed that, at the end of three hour study duration, only about 26% w/w of the pure SCE 428 
permeated through the everted intestine. The physical mixture (PM) showed a marginal, but a 429 
non-significant improvement in the permeation of SCE. The prepared CN, however, 430 
demonstrated a significantly improved permeation of SCE across the everted intestine. At the 431 
end of three hour testing period over 80 % w/w of SCE was found to permeate across the 432 
biological membrane. The phospholipids being amphiphilic in nature, may behave as surfactants 433 
and contribute towards the increased permeability of the drug across the membrane. Due to the 434 
observed improved solubility, increased dissolution rate, and observed increased permeability of 435 
the SCE in the prepared CN, this approach of the drug-phospholipid complexation lends itself to 436 
be a promising formulation strategy for the enhanced delivery of SCE to the physiology. 437 
Preliminary pharmacological evaluation (in-vivo efficacy) 438 
The results of the preliminary pharmacological evaluation (in-vivo efficacy) of the prepared 439 
SCE-Phospholipid complex (CN) are shown in the Figure 7. A group of young mice (n=6) was 440 
treated with the vehicle (saline). The aged mice (n=6/group) were administered with vehicle 441 
(saline), Phospholipon® 90H (900 mg/kg), piracetam (200 mg/kg), SCE (300 mg/kg), or CN 442 
(300 mg/kg SCE equivalent) via oral route.  As shown in the Figure 7A. It was observed that the 443 
escape latency i.e. the time taken by the animal to locate the platform, in the young mice treated 444 
with vehicle progressively and significantly decreased during the five-day training period. This 445 
indicated a quicker learning and adaptation to the surroundings by these animals. The aged 446 
animals treated with the vehicle, however, exhibited a significantly higher escape latency (p < 447 
0.01 on day 2, p < 0.001 on day 3 and 4), that did not appear to significantly improve at the end 448 
of five-day training period. The aged animals treated with piracetam, SCE, or CN showed a 449 
significant decrease in the escape latency at the end of five-day training period. The application 450 
of two-way ANOVA showed the main effect of treatments [F (4,100) = 26.02, p < 0.0001], 451 
acquisition days [F (3,100) =81.45, p < 0.0001], and their interaction [F (12,100) = 2.906, p < 452 
0.01].  The post-hoc Bonferroni multiple comparison test also revealed that all the treatments 453 
(piracetam, p < 0.001 on day 3 and 4; SCE, p < 0.05 on day 3, and p < 0.01 on day 4, or CN, p < 454 
0.01on day 2 and p < 0.001 on day 3 and 4) in aged animals significantly reduced escape latency 455 
on day two onward as compared to the vehicle treated aged animal group.  While the CN and 456 
piracetam showed similar effects on the escape latency (p > 0.05), CN exhibited higher efficacy 457 
in terms of reduction in the escape latency as compared to the pure SCE (p < 0.05). However, a 458 
four-day alone treatment with Phospholipon® 90H in aged mice did not reveal any 459 
significant improvements in the escape latency compared to the vehicle treated mice. 460 
 In addition, the application of one-way ANOVA showed a significant effect of piracetam, 461 
SCE or CN treatments on time spent in the target quadrant [F (4, 29) = 6.221, p < 0.01] at the 462 
end of five days (Figure 7B). The Bonferroni multiple comparison test revealed that aged 463 
animals treated with vehicle did not recognize the target quadrant, and therefore spent less time 464 
in that quadrant compared to the vehicle-treated young animals (p < 0.05).  However, oral 465 
treatments of piracetam (p < 0.01), SCE (p < 0.05), or CN (p < 0.01) significantly increased the 466 
time spent in the target quadrant compared to the vehicle-treated aged animals, thus confirming 467 
the potential effect of centella extract on memory as reported in earlier studies (37, 38).  468 
Centella extract is known to improve the morphology and arborization of hippocampal 469 
neuronal dendrites (52, 53). Moreover its negative effect on reactive oxygen species and 470 
superoxide formation along with decrease in glutathione, activation of glutathione-S-471 
transferase, have reportedly the key mechanisms involved in its nootropic action (37).  472 
It was interesting to note here that, CN treatment showed a comparable effect to 473 
that of the standard piracetam treatment (p > 0.05) i.e., the CN treated animals spent more 474 
time in the target quadrant.  The SCE treated mice, while showed an increased time spent 475 
in the target quadrant compared to the vehicle group, this effect was not statistically 476 
significant. Thus we suggest that although both, SCE or CN administration improves the 477 
spatial learning and memory in aged mice, CN exhibits better efficacy compared to SCE in 478 
MWM. The improvement in the relative absorption of CN after oral administration might 479 
be attributed to the following factors: SCE being lipophilic in nature, its absorption and 480 
bioavailability is dissolution rate limited. Interactions between the non-polar, fatty acid 481 
component of phospholipid and the SCE could have enhanced the overall hydrophilicity 482 
and solubility of CN (3). This may have possibly resulted in an improved dissolution 483 
efficiency of the CN. In addition, the smaller particle size of the prepared CN might have 484 
led to enhanced relative absorption of SCE after oral administration. The extended release 485 
of SCE from CN, along with a decreased metabolism may also confer a prolonged duration 486 
of action and higher bioavailability (28). Furthermore, as reported in the previous studies, 487 
the intestinal transport and the absorption mechanisms might also be the possible 488 
contributors to the improved CN oral bioavailability (54, 55).  489 
Several studies have previously reported the influence of phospholipids on memory 490 
improvement (56-59). Since a phospholipid was employed in the present study as a carrier 491 
for the SCE in the formulation of the CN, we examined the possibility of the memory-492 
enhancement effects of Phospholipon® 90H. The results from Phospholipon® 90H-treated 493 
aged mice group showed no significant improvement in the escape latency or the time spent 494 
in the target quadrant after a four day treatment period. Nagata et. al and Yaguchi et. al in 495 
their studies noted that oral administration of 1,2-dilynoleoylsnglycero-3-phosphocholine 496 
(DLPhtCho) alone or in combination with 1-palmitoyl-2-oleoylsnglycero-3-phosphocholine 497 
(POPhtCho) predominantly blocked the scopolamine induced dementia, but these effects 498 
were less pronounced in normal animals (57, 58). Additionally, unlike the four-day 499 
treatment protocol employed in the present study, previous studies evaluating 500 
phospholipids followed longer durations of drug treatment, which may have contributed to 501 
the improved learning and memory observed with phospholipids (57, 59, 60). The dose and 502 
the duration of therapy appears to be important parameters in the pro-cognitive effects 503 
observed with phospholipids. Thus, in the present study, the improved learning and 504 
memory following CN treatment can be attributed purely to the intrinsic action of Centella 505 
extract, and the contribution of Phospholipon® 90H appears to be non-significant.  506 
Conclusions 507 
In the present study, an attempt was made to enhance the aqueous solubility of SCE via its 508 
complexation with phospholipids (preparation of naturosomes). A central composite design was 509 
used to optimize the formulation and process variables. The prepared CN were evaluated for 510 
physicochemical, functional, and pharmacological attributes. The FTIR, DSC, PXRD, 511 
photomicroscopy, and the SEM studies indicated the successful formation of vesicular drug-512 
phospholipid complex. The apparent solubility, the in-vitro dissolution, and the ex-vivo 513 
permeability studies indicated a significant improvement in the aqueous solubility, the drug 514 
release, and the membrane permeation of the SCE from the CN, respectively. The preliminary 515 
in-vivo pharmacological evaluation revealed a significantly higher efficacy (likely due to 516 
improved bioavailability) of the prepared CN compared to the pure extract, and a comparable 517 
efficacy with the standard drug, piracetam (200 mg/kg).  The exact mechanism of the improved 518 
efficacy of the prepared CN, as well as the contribution of individual triterpenes to the 519 
pharmacological activity will require further detailed investigation. Additional studies analyzing 520 
the pharmacokinetic parameters are required to substantiate the increased absorption, and the 521 
enhanced bioavailability hypothesis. 522 
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Response to reviewer’s comments 
Reviewers' Comments: 
Editorial office note: 
1. ALL experimental and estimated values should be reported to 3 significant figures only, 
unless justification is explicitly stated to document a higher degree of accuracy.  Errors 
should not be provided with a higher degree of accuracy than the mean value, for example  
20.2 +/- 3.55 should be written as 20.2 +/- 3.6. 
RESPONSE: Suggestions have been incorporated in the revised manuscript. 
 
2. Please reduce the total number of figures + tables to no more than 10, in compliance with the 
INSTRUCTIONS TO AUTHORS. Some of the less important figures and tables can be 
moved to be SUPPLEMENTARY MATERIALS, which will be linked to the article, and 
accessible to readers. Please adjust the text accordingly in reference to the altered numbering 
of the figures and tables. 
RESPONSE: We have reduced the number of figures to 7 and the number of tables to 3, in 
compliance with the total number not to exceed 10. 
 
Editor's comments: 
Please address the reviewer's comments, and also please add a scale bar to Figure 3. 
RESPONSE: A scale bar is now added to the figure. The figure is now moved to be 
supplementary materials (Suppl. Figure 2). 
Reviewer #1:  
1. Nicely written article. 
RESPONSE: Thank you, the authors appreciate the encouragement. 
2. Reviewer will highly encourage to add more discussion for pharmacological evaluations. 
RESPONSE: The pharmacological evaluations are further elaborated in the manuscript. 
3. Reviewer will recommend adding a separate section correlating the solubility/ dissolution/ 
release studies with animal studies presented in the manuscript. 
RESPONSE: Additional discussion correlating the solubility/dissolution with animal 
studies added to the manuscript. 
 
 
Reviewer #2:  
The authors describe the generation of a phospholipid-Standardized Centella Extract (SCE) 
complex for the treatment of Alzheimer's disease.  It was proposed that complexing this 
phytoconstituent with phospholipids would allow for an increase in aqueous solubility, 
dissolution rate, and permeation rate compared to pure SCE.  A quality by design approach was 
employed to optimize the encapsulation efficiency of the SCE.  In-vitro dissolution studies and 
ex-vivo permeation studies were performed to characterize the physiochemical properties of the 
complex.  An in-vivo pharmacological study was performed to test the efficiency of the complex. 
 
1. Figure 11: It seems that the mice treated with SCE and CN perform very similarly in 
experiment A and B. The significance in difference is very minimal and seems to be 
overstated by the authors. Moreover, a difference in Figure 11B of 2-3 seconds of time spent 
in target quadrant is most likely not biologically relevant. The authors should rephrase their 
discussion and their conclusion. 
RESPONSE: The reviewer’s comments are duly noted, and the discussion is appropriately 
rephrased. 
A brief explanation: 
The effect of SCE and CN on learning and memory was assessed in the aged mice (figure 
7A and B). We noted that piracetam, (p < 0.001 on day 3 and 4), SCE (p < 0.05 day 3 and p 
< 0.01 on day 4), PM (p < 0.05 day 3 and p < 0.01 on day 4) and CN (p < 0.05 on day 2 and 
p < 0.001 on day 3 and 4) significantly decreased the escape latency, indicating improved 
learning and memory in aged mice.  While these results emphasize the effectiveness of SCE 
in age related dementia, CN showed greater efficacy as compared to SCE. The escape 
latencies for both the treatment groups were as follows: 
Days Aged mice+SCE (sec) Aged mice+CN (sec) Difference (sec) 
1 115.1 107.3 -7.810 
2 89.64 77.31 -12.33 
3 73.81 58.64 -15.17 
4 55.37 25.82 -29.55 
  
Statistical analysis (Bonferroni multiple comparison post hoc tests) of this data noted that, 
4 day treatment of CN significantly decreased the escape latencies in aged mice as 
compared to SCE (p<0.05), indicating the superiority of CN over SCE.  These effects may 
be attributed to the improved solubility and thus bioavailability in in-vivo studies.   
Although CN treated animals spent higher time in searching platform in the target 
quadrant as compared with SCE treated animals, the observed difference was not 
statistically significant. The reason behind this observation is not well understood, but we 
may speculate that a continuous four-day treatment of centella extract through both the 
formulations produced long term effects on memory in the aged animals, and thus 
significantly increased time spent in the target quadrant. Interestingly, a significant time 
spent in the target quadrant was exhibited only in CN treated animals (p<0.05) but not in 
SCE (p<0.05) treated group as compared to vehicle treated aged mice. These observations 
enabled us to conclude that the formulated CN exhibits improved bioavailability and 
efficacy in the treatment of Alzheimer’s disease. 
2. Pharmacological evaluation of the formulations: First, the authors should treat the mice with 
the Phospholipon 90H alone as a control.  This is relevant because there is some evidence 
that lipids alone could reduce cognitive decline. For example, the Phospholipid Intervention 
for Cognitive Ageing Reversal investigates if phospholipids demonstrate cognitive benefits 
and memory retention benefits.   Second, the authors should treat the mice with a control of 
the physical mixture of SCE and phospholipid.  These controls were performed during the in-
vitro and ex-vivo studies and the reviewer believes they should be included in the in-vivo 
study as well. Reference: Scholey, A.B., et al., A randomized controlled trial investigating 
the neurocognitive effects of Lacprodan(R) PL-20, a phospholipid-rich milk protein 
concentrate, in elderly participants with age-associated memory impairment: the 
Phospholipid Intervention for Cognitive Ageing Reversal (PLICAR): study protocol for a 
randomized controlled trial. Trials, 2013. 14: p. 404. 
RESPONSE: The authors understand the reviewer’s concern about per se effect of 
Phospholipon 90H on learning and memory. Therefore, we administered 900 mg/kg of 
Phospholipon 90H alone orally, and 1-hr thereafter the animals were subjected to 
MWM test. We did not observe any significant improvement in the escape latency or 
the time spent in the target quadrant, suggesting no effect of four-day treatment of 
Phospholipon 90H on learning and memory. The administration of the physical mixture 
of Phospholipon 90H-SCE to the aged mice exhibited similar escape latency as that of 
SCE treated animals. 
Additional discussion is incorporated in the manuscript. 
3. The authors claim in the first sentence of the abstract that the goal of the work was to 
improve the bioavailability of the phytoconstituent. Although, higher solubility was observed 
in vitro, this did not translate in better efficacy under in vivo conditions (SCE compared to 
CN. The authors should discuss why the higher solubility did not translate to better 
pharmacological effects/or why higher solubility does not necessarily mean better 
bioavailability (depends on the properties of the drugs). 
RESPONSE: discussion is incorporated in the manuscript. 
4. The authors used dynamic light scattering (DLS) and scanning electron microscopy (SEM) as 
techniques to quantify the size of the CN.  There is a discrepancy between the size of the 
particle suggested by DLS, ~450 nm, and the size of the particles calculated by the reviewer 
using the scale bars included in Figure 4 (around 18 μm for Figure 4C).  DLS may be an 
inappropriate technique to use because irregular shaped particles, such as the CN, will scatter 
light depending largely on the orientation of the particle in solution.  If the SEM images are 
to be trusted, than the author's argument regarding the ability of smaller particles (<500 nm) 
to cross epithelial cell membranes via endocytosis is invalid for their proposed technology. 
RESPONSE: The authors acknowledge reviewer’s observations. The SEM and 
photomicroscopy techniques were used mainly to understand the surface morphology of 
the prepared CN, rather than particle size. Multiple replicates of CN samples evaluated 
with DLS showed a mean particle size of 450.1 ± 20.0 nm. While imaging may give some 
approximation of the size, considering the heterogeneity in the nature of the prepared 
particles, limited field of view, and the operator bias, the authors believe that SEM may not 
provide an accurate estimate of the particle size. 
Minor point: 
1. The authors abbreviated CN (Centella Naturosome) in the abstract and did not include an 
explanation.  The explanation was however later clarified in the introduction. 
RESPONSE: Comment noted. Changes are made to the abstract to reflect the explanation 
of the abbreviation. 
Table 1: Coded levels and “Real” values for each factor under study 
 
Table 2: Central composite design formulation batches with respective entrapment efficiencies. * 
Values represent mean ± standard deviation (n=3) 
 
 
Table 3: Solubility study of SCE, PM and CN. *Data expressed as mean ± Std. Dev.; n = 3 
 
 
Table 1: Coded levels and “Real” values for each factor under study 
Variables Levels -1.7 -1 0 +1 +1.7 
Independent  Real values 
Phospholipid : drug ratio (X1, w:w) 0.5 1.0 1.8 2.5 3.0 
Reaction temperature (X2, °C) 40.0 44.0 50.0 56.0 60.0 
Reaction time (X3, h) 1.0 1.4 2.0 2.6 3.0 
Dependent  
Entrapment efficiency (Y, % w/w) 
 
Table 2: Central composite design formulation batches with respective entrapment efficiencies. 
Batches X1 X2 X3 Entrapment efficiency* (%, w/w) 
F1 -1 +1 +1 83.2 ± 1.3 
F2 -1 -1 +1 89.2 ± 0.8 
F3 +1.7 0 0 95.1 ± 1.1 
F4 +1 -1 +1 86.4 ± 1.3 
F5 0 0 -1.7 76.7 ± 0.9 
F6 -1.7 0 0 58.1 ± 1.1 
F7 0 0 +1.7 94.4 ± 1.2 
F8 +1 +1 +1 94.3 ± 1.0 
F9 0 -1.7 0 79.4 ± 0.9 
F10 -1 -1 -1 64.7 ± 0.9 
F11 -1 +1 -1 71.5 ± 0.8 
F12 0 +1.7 0 90.9 ± 1.3 
F13 +1 +1 -1 90.0 ± 1.1 
F14 +1 -1 -1 82.2 ± 1.6 
F15- F20 0 0 0 91.4 ± 0.9 
* Values represent mean ± standard deviation (n=3) 
 
 
Table 3: Solubility study of SCE, PM and CN. 
Sample Aqueous solubility (μg/ml)* n-Octanol solubility (μg/ml)* 
SCE 8.12 ± 0.44 325.33 ± 6.71 
PM 13.58 ± 0.35 331.08 ± 5.89 
CN 98.01 ± 1.37 343.16 ± 7.21 
*Data expressed as mean ± Std. Dev.; n = 3 
 
 
Fig. 1. Pareto diagrams for effect estimation. The effects presenting probability values higher 
than 0.05 are not considered as statistically significant 
Fig. 2. FTIR spectra of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN. 
Fig. 3. DSC thermograms of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN. 
Fig. 4. PXRD spectra of (A) SCE, (B) phospholipid, (C) physical mixture, (D) CN. 
Fig. 5. In vitro dissolution study of SCE, PM and CN 
Fig. 6. Ex Vivo permeability study of SCE, PM and CN 
Fig. 7. Effect of Standardized Centella Extract (SCE) and Centella Naturosomes (CN) on spatial 
learning and memory in the Morris Water Maze (MWM) test. (A) Young and aged animals were 
treated with vehicle (saline), Phospholipon® 90H (900 mg/kg), piracetam (200 mg/kg), SCE (300 
mg/kg), physical mixture (equivalent to 300 mg/kg SCE), or CN (equivalent to 300 mg/kg SCE) 
via oral route, and 1 hour later subjected to assessment of escape latency in a four-day 
acquisition trial in MWM test. Data are expressed as mean ± SEM.  *p < 0.01, **p < 0.001 vs 
young mice + vehicle; #p < 0.05, # #p < 0.01, # # #p < 0.001 vs aged mice + vehicle. (B) Total time 
spent by the animals in the target quadrant during the probe trial on day 5. Data are expressed as 
mean ± SEM.  *p < 0.05 vs young mice + vehicle; #p < 0.05, # #p < 0.01 vs aged mice + vehicle. 
 
 
 
 
 
  







